Results 1 to 10 of about 944,744 (294)
Cancers, 2011 Much of our knowledge regarding cancer immunotherapy has been derived from sarcoma models. However, translation of preclinical findings to bedside success has been limited in this disease, though several intriguing clinical studies hint at the potential ...
Gouw, Launce G +3 more
core +6 more sources
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group [PDF]
Journal of Immunotherapy for Cancer, 2017 Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
I. Puzanov +81 more
semanticscholar +3 more sources
Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges
Frontiers in Immunology, 2023 Chimeric antigen receptor (CAR) T cells are “living drugs” that specifically recognize their target antigen through an antibody-derived binding domain resulting in T cell activation, expansion, and destruction of cognate target cells.
Dennis Christoph Harrer +7 more
doaj +1 more source
Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy [PDF]
Allergy, 2020 AbstractIgE‐mediated food allergy remains a significant and growing problem across the globe. Of the various treatment modalities, oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT) have been the best studied. Across various studies of OIT for egg, milk, and peanut allergy, strong levels of desensitization have been shown.
Edwin H. Kim, Arvil Wesley Burks
openaire +3 more sources
Cells, 2022 The advent of chimeric antigen receptor (CAR) T cells expedited the field of cancer immunotherapy enabling durable remissions in patients with refractory hematological malignancies.
Dennis Christoph Harrer +9 more
doaj +1 more source
Immunotherapy of aspergillosis [PDF]
Clinical Microbiology and Infection, 2012 Management of invasive aspergillosis in high-risk patients remains challenging. There is an increasing demand for novel therapeutic strategies aimed at enhancing or restoring antifungal immunity in immunocompromised patients. In this regard, modulation of specific innate immune functions and vaccination are promising immunotherapeutic strategies ...
Cristina Cunha +4 more
openaire +4 more sources
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
Nature Communications, 2023 Chimeric Antigen Receptor (CAR) T cells directed to B cell maturation antigen (BCMA) mediate profound responses in patients with multiple myeloma, but most patients do not achieve long-term complete remissions.
Rebecca C. Larson +14 more
doaj +1 more source
Lung cancer immunotherapy: progress, pitfalls, and promises
Molecular Cancer, 2023 Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy.
Aritraa Lahiri +7 more
semanticscholar +1 more source
Breast Cancer Research, 2023 Background B7 homology 4 (B7-H4), a potential target for cancer therapy, has been demonstrated to inhibit T cell cytotoxicity in the early stages of breast cancer.
Linlin Zhou +7 more
doaj +1 more source
IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities
Frontiers in Immunology, 2023 Chimeric antigen receptor (CAR) modified T cells can induce complete remissions in patients with advanced hematological malignancies. Nevertheless, the efficacy is mostly transient and remains so far poor in the treatment of solid tumors.
Dennis Christoph Harrer +5 more
doaj +1 more source